Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Expression of endothelin 2 and localized clear cell renal cell carcinoma.

Bot BM, Eckel-Passow JE, LeGrand SN, Hilton T, Cheville JC, Igel T, Parker AS.

Hum Pathol. 2012 Jun;43(6):843-9. doi: 10.1016/j.humpath.2011.07.011. Epub 2011 Nov 1.

2.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

3.

C-lysine conjugates: pH-controlled light-activated reagents for efficient double-stranded DNA cleavage with implications for cancer therapy.

Yang WY, Breiner B, Kovalenko SV, Ben C, Singh M, LeGrand SN, Sang QX, Strouse GF, Copland JA, Alabugin IV.

J Am Chem Soc. 2009 Aug 19;131(32):11458-70. doi: 10.1021/ja902140m.

4.

Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma.

Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA.

Clin Cancer Res. 2007 Aug 15;13(16):4740-9.

5.

Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.

Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood CG.

Oncogene. 2003 Sep 11;22(39):8053-62.

PMID:
12970754

Supplemental Content

Loading ...
Support Center